Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s point-of-care Car-T push looks to have stalled.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
